High ECM2 Expression Predicts Poor Clinical Outcome and Promotes the Proliferation, Migration, and Invasiveness of Glioma.
Junsheng LiSiyu WangQiheng HeFa LinChuming TaoYaowei DingJia WangJi-Zong ZhaoWen WangPublished in: Brain sciences (2023)
The study suggested the potential of ECM2 as a novel immune-associated prognostic biomarker and therapeutic target for glioma patients.